(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
28 November 2013 (28.11.2013)

WIPO | PCT

(10) International Publication Number
WO 2013/174509 A1

(51) **International Patent Classification**:
A61K 39/395 (2006.01) *A61K 45/06* (2006.01)
C07K 16/30 (2006.01)

(21) **International Application Number**:
PCT/EP2013/001503

(22) **International Filing Date**:
21 May 2013 (21.05.2013)

(25) **Filing Language**: English

(26) **Publication Language**: English

(30) **Priority Data**:
PCT/EP2012/002211 23 May 2012 (23.05.2012) EP

(71) **Applicants**: **GANYMED PHARMACEUTICALS AG** [DE/DE]; Freiligrathstrasse 12, 55131 Mainz (DE). **TRON - TRANSLATIONALE ONKOLOGIE AN DER JOHANNES GUTENBERG-UNIVERSITÄT MAINZ GEMEINNÜTZIGE GMBH** [DE/DE]; Langenbeckstrasse 1, 55131 Mainz (DE).

(72) **Inventors**: **SAHIN, Ugur**; Philipp-von-Zabern-Platz 1, 55116 Mainz (DE). **TÜRECI, Özlem**; Philipp-von-Zabern-Platz 1, 55116 Mainz (DE). **MITNACHT-KRAUS, Rita**; Taunusstrasse 45, 61169 Friedberg (DE). **JACOBS, Stefan Denis**; Friedenstrasse 7, 55252 Mainz-Kastel (DE). **UTSCH, Magdalena Jadwiga**; Fingerkrautweg 30b, 55262 Heidesheim am Rhein (DE). **HEINZ, Cornelia Adriana Maria**; Auf den Elfmorgen 22, 55278 Dalheim (DE). **STADLER, Christiane Regina**; Darmstädter Strasse 76, 64625 Bensheim (DE).

(74) **Agents**: **SCHNAPPAUF, Georg** et al.; ZSP Patentanwälte, Partnerschaftsgesellschaft, Radlkoferstrasse 2, 81373 München (DE).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *with (an) indication(s) in relation to deposited biological material furnished under Rule 13bis separately from the description (Rules 13bis.4(d)(i) and 48.2(a)(viii))*

— *with sequence listing part of description (Rule 5.2(a))*

WO 2013/174509 A1

(54) **Title**: COMBINATION THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER

(57) **Abstract**: The present invention provides a combination therapy for effectively treating and/or preventing diseases associated with cells expressing CLDN18.2, including cancer diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder and metastases thereof.